Clinical trials: Advanced HIV Disease
Human Immunodeficiency Virus; HIV
An Immunologic Study of Treatment-Naive HIV Patients Starting a Darunavir/Ritonavir- or Efavirenz-Based HAART
The purpose of this study is to study the kinetics (study of the rate of change) of immune recovery quality and function in stored plasma blood samples of treatment-naive (not previously treated with antiretroviral drugs)…
- Trial name
- NCT01541085
- Testing
- Darunavir/Ritonavir (DRV/r), Efavirenz (EFV)
- Volunteers
- 33 people
- Sponsor
- Janssen-Cilag S.p.A.
HIV Infections
A Study of Multiple Doses of Vesnarinone in Advanced HIV Disease
To evaluate the safety and tolerability of four doses of oral vesnarinone in patients with advanced HIV disease.
- Trial name
- NCT00002337
- Testing
- Vesnarinone
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- Otsuka America Pharmaceutical
HIV Infections
A Study of Saquinavir and Zalcitabine, Used Alone and Together, in the Treatment of Advanced HIV Infection in Patients Who Stopped Taking or Who Cannot Take Zidovudine
To compare the safety, tolerance, and efficacy of saquinavir mesylate (Ro 31-8959) alone, zalcitabine (dideoxycytidine; ddC) alone, and both in combination, in patients discontinuing or unable to take zidovudine (AZT).
- Trial name
- NCT00002333
- Testing
- Saquinavir, Zalcitabine
- Where
- 47 sites in United States, Canada and 1 more
- Volunteers
- 900 people
- Sponsor
- Hoffmann-La Roche
Sarcoma, Kaposi, HIV Infections
Topical Use of 4,4'-Dihydroxybenzophenone-2,4-Dinitrophenylhydrazone (A-007) in the Treatment of Advanced Malignancies Including Kaposi's Sarcoma and Lymphoproliferative Disorders
To evaluate topical A-007 in patients with advanced malignancies including Kaposi's sarcoma and lymphoproliferative disorders.
- Conditions
- Sarcoma, Kaposi, HIV Infections, Lymphoproliferative Disorders
- Trial name
- NCT00002153
- Testing
- A-007
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- DEKK-TEC, Inc.
HIV Infections
Open-Label Program of Dideoxycytidine ( ddC ) to Be Used in Combination With Zidovudine ( AZT ) for Treatment of Advanced HIV Disease
To provide zalcitabine ( dideoxycytidine; ddC ) for use with zidovudine ( AZT ) in patients with advanced HIV infection. To observe serious toxicities in this population.
- Trial name
- NCT00002081
- Testing
- Zidovudine, Zalcitabine
- Where
- United States
- Sponsor
- Hoffmann-La Roche
HIV Infections
A Phase I/II Study of the Safety, Tolerance, and Pharmacokinetics of 9-(2-Phosphonylmethoxyethyl)Adenine ( PMEA; Adefovir ) in Patients With Advanced HIV Disease.
To study the safety, tolerance, pharmacokinetics, and anti-HIV effects of PMEA ( adefovir ) when administered daily by intravenous (IV) and/or subcutaneous (SC) injection in patients with advanced HIV disease.
- Trial name
- NCT00002115
- Testing
- Adefovir
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Gilead Sciences
HIV Infections
Safety Study of Tipranavir Co-administered With Low-dose Ritonavir (TPV/r) in Patients With Advanced HIV-1 Infection and Limited Treatment Options
This study evaluated the safety and tolerability of tipranavir to improve treatment options for HIV type 1-infected patients who have been previously treated and whose treatment is no longer effective.
- Trial name
- NCT00144287
- Testing
- Tipranavir/Ritonavir
- Where
- 53 sites in Germany
- Volunteers
- 255 people
- Sponsor
- Boehringer Ingelheim
HIV Infections
Phase III Randomized Double-Blind Placebo Controlled Study To Evaluate the Safety and Efficacy of Betaseron in AIDS and Advanced ARC Patients Receiving a Reduced-Dose AZT Regimen
To evaluate the safety and efficacy of interferon beta (Betaseron) in AIDS and advanced AIDS related complex (ARC) patients receiving a reduced-dose zidovudine (AZT) regimen.
- Trial name
- NCT00002238
- Testing
- Interferon beta-1b, Zidovudine
- Where
- 25 sites in United States
- Sponsor
- Bayer
HIV Infections, Cytopenias
The Safety and Effectiveness of r-HuEPO in Patients With AIDS or Advanced AIDS-Related Complex (ARC) Who Are Anemic
To determine the safety and efficacy of erythropoietin administered to patients with AIDS or advanced AIDS related complex ARC and anemia.
- Trial name
- NCT00002303
- Testing
- Epoetin alfa
- Where
- United States
- Sponsor
- Ortho Pharmaceuticals
HIV Infections
Study of Itraconazole in Patients With Advanced HIV Infection
To demonstrate a dosage regimen for intravenous itraconazole that produces a plasma concentration range comparable to that obtained after currently used oral dosages of itraconazole oral solution; and to obtain preliminary safety…
- Trial name
- NCT00002370
- Testing
- Itraconazole
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Janssen, LP
HIV Infections
An Open-Label, Multicenter Study to Evaluate the Safety and Tolerability of Dideoxycytidine (ddC) in Patients With AIDS or Advanced ARC Who Previously Demonstrated Intolerance to Zidovudine (AZT) in Protocol N3300 or N3492
To demonstrate that zalcitabine (dideoxycytidine; ddC) monotherapy is safe and tolerable in the treatment of patients with AIDS or advanced AIDS related complex (ARC) who previously demonstrated intolerance to zidovudine (AZT)…
- Trial name
- NCT00002265
- Testing
- Zalcitabine
- Where
- 9 sites in United States
- Sponsor
- Hoffmann-La Roche
HIV Infections
Dideoxycytidine ( Ro 24-2027 ). A Treatment Protocol for the Use of Dideoxycytidine ( ddC ) in Patients With AIDS or Advanced ARC Who Cannot Be Maintained on Zidovudine ( AZT ) Therapy.
To provide zalcitabine ( ddC ) for patients with AIDS or Advanced ARC in whom zidovudine ( AZT ) is contraindicated, or who have failed treatment with or are intolerant to AZT and to demonstrate that ddC monotherapy is safe, and…
- Trial name
- NCT00002256
- Testing
- Zalcitabine
- Where
- United States
- Sponsor
- Hoffmann-La Roche
Sarcoma, Kaposi, HIV Infections
Paclitaxel in Advanced Refractory Kaposi's Sarcoma (AIDS-KS): A Phase II Trial of Paclitaxel From Baker Norton Pharmaceuticals
To determine response rate, median time to tumor progression, qualitative and quantitative toxicity and reversibility of toxicity in patients with advanced refractory AIDS-associated Kaposi's sarcoma (KS) administered a 3-hour…
- Trial name
- NCT00002189
- Testing
- Paclitaxel
- Where
- United States
- Sponsor
- Baker Norton Pharmaceuticals
HIV Infections
A Study of WF 10 IV Solution in Patients With Advanced HIV Disease
The purpose of this study is to see if it is safe and effective to give WF 10 (TCDO) to patients with advanced HIV disease who cannot or will not take zidovudine, didanosine, zalcitabine, or stavudine.
- Trial name
- NCT00002152
- Testing
- WF10
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Oxo Chemie GmbH
HIV Infections, Cytopenias
A Double-Blind, Placebo-Controlled Study With Open-Label Follow-Up To Determine the Safety and Efficacy of r-HuEPO in AIDS and Advanced ARC Patients With Anemia
To determine the safety and efficacy of r-HuEPO administration to patients with AIDS or advanced AIDS related complex (ARC) and anemia secondary to their disease.
- Trial name
- NCT00002042
- Testing
- Epoetin alfa
- Where
- United States
- Sponsor
- Ortho Pharmaceuticals
HIV Infections
Trial of an Alternative Dosing Regimen of Oral Retrovir in Patients With AIDS or Advanced ARC
To evaluate the safety and tolerance, in patients with severe clinical manifestations of HIV infection, of zidovudine (AZT) administered daily for 48 weeks as a low dose every 4 hours or a higher dose every 12 hours.
- Trial name
- NCT00002020
- Testing
- Zidovudine
- Where
- 12 sites in United States, Puerto Rico
- Sponsor
- Glaxo Wellcome
HIV Infections
A Third-Party Blinded, Placebo Controlled Comparative Study of AS-101 Administered Intravenously in HIV Positive Patients With Advanced Disease
To compare the effect of AS-101 to that of placebo on clinical efficacy and immunologic function in HIV positive patients with advanced disease.
- Trial name
- NCT00002033
- Testing
- Zidovudine, AS-101
- Where
- 4 sites in Brazil
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
HIV Infections
Phase I Rising Dose Tolerability Study of SC-48334 in Patients With Acquired Immunodeficiency Syndrome (AIDS) and Advanced AIDS Related Complex
To determine the following about the use of SC-48334 in patients with AIDS and advanced AIDS related complex (ARC): 1. The largest maximum tolerated dose (MTD); 2. Effectiveness against HIV; 3.
- Trial name
- NCT00000692
- Testing
- Butyldeoxynojirimycin
- Where
- 6 sites in United States
- Volunteers
- 48 people
- Sponsor
- G D Searle
HIV Infections
A Study of Enfuvirtide (Fuzeon) in Participants With Advanced Human Immunodeficiency Virus (HIV) Infection
This study assessed the safety and tolerability of enfuvirtide in participants with advanced HIV genotype 1 (HIV-1) disease. Eligible participants who failed treatment with regimens containing at least one product from each…
- Trial name
- NCT02582983
- Testing
- Enfuvirtide
- Where
- 5 sites in Thailand
- Volunteers
- 23 people
- Sponsor
- Hoffmann-La Roche
HIV Infections
A Study of Enfuvirtide (Fuzeon) in Patients With Advanced Human Immunodeficiency Virus-1 (HIV-1) Infection
This study will evaluate the safety and tolerability of subcutaneous Fuzeon in patients with advanced HIV-1 infection unable to construct an appropriate treatment regimen from currently available antiretroviral agents.
- Trial name
- NCT02569502
- Testing
- enfuvirtide
- Where
- Bulgaria
- Volunteers
- 6 people
- Sponsor
- Hoffmann-La Roche